Loading...
Addition of Docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness
Woods, Beth S. Sideris, Eleftherios Sydes, Matthew R. Gannon, Melissa R. Parmar, Mahesh K.B. Alzouebi, Mymoona Attard, Gerhardt Birtle, Alison J. Brock, Susannah Cathomas, Richard
Woods, Beth S.
Sideris, Eleftherios
Sydes, Matthew R.
Gannon, Melissa R.
Parmar, Mahesh K.B.
Alzouebi, Mymoona
Attard, Gerhardt
Birtle, Alison J.
Brock, Susannah
Cathomas, Richard
Authors
Woods, Beth S.
Sideris, Eleftherios
Sydes, Matthew R.
Gannon, Melissa R.
Parmar, Mahesh K.B.
Alzouebi, Mymoona
Attard, Gerhardt
Birtle, Alison J.
Brock, Susannah
Cathomas, Richard
Chakraborti, Prabir R.
Cook, Audrey
Cross, William R.
Dearnaley, David P.
Gale, Joanna
Gibbs, Stephanie
Graham, John D.
Hughes, Robert
Jones, Rob J.
Laing, Robert
Mason, Malcolm D.
Matheson, David
McLaren, Duncan B.
Millman, Robin
O'Sullivan, Joe M.
Parikh, Omi
Parker, Christopher C.
Peedell, Clive
Protheroe, Andrew
Ritchie, Alastair W.S.
Robinson, Angus
Russell, J. Martin
Simms, Matthew S.
Srihari, Narayanan N.
Srinivasan, Rajaguru
Staffurth, John N.
Sundar, Santhanam
Thalmann, George N.
Tolan, Shaun
Tran, Anna T.H.
Tsang, David
Wagstaff, John
James, Nicholas D.
Sculpher, Mark J.
Sideris, Eleftherios
Sydes, Matthew R.
Gannon, Melissa R.
Parmar, Mahesh K.B.
Alzouebi, Mymoona
Attard, Gerhardt
Birtle, Alison J.
Brock, Susannah
Cathomas, Richard
Chakraborti, Prabir R.
Cook, Audrey
Cross, William R.
Dearnaley, David P.
Gale, Joanna
Gibbs, Stephanie
Graham, John D.
Hughes, Robert
Jones, Rob J.
Laing, Robert
Mason, Malcolm D.
Matheson, David
McLaren, Duncan B.
Millman, Robin
O'Sullivan, Joe M.
Parikh, Omi
Parker, Christopher C.
Peedell, Clive
Protheroe, Andrew
Ritchie, Alastair W.S.
Robinson, Angus
Russell, J. Martin
Simms, Matthew S.
Srihari, Narayanan N.
Srinivasan, Rajaguru
Staffurth, John N.
Sundar, Santhanam
Thalmann, George N.
Tolan, Shaun
Tran, Anna T.H.
Tsang, David
Wagstaff, John
James, Nicholas D.
Sculpher, Mark J.
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2018-09-14
Submitted date
Alternative
Abstract
Background Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic disease and prolongs failure-free survival for those without. To date there has been no formal assessment of whether funding docetaxel in this setting represents an appropriate use of UK National Health Service (NHS) resources. Objective To assess whether administering docetaxel to men with PC starting long-term hormone therapy is cost-effective in a UK setting. Design, setting, and participants We modelled health outcomes and costs in the UK NHS using data collected within the STAMPEDE trial, which enrolled men with high-risk, locally advanced metastatic or recurrent PC starting first-line hormone therapy. Intervention SOC was hormone therapy for ≥2 yr and radiotherapy in some patients. Docetaxel (75 mg/m2) was administered alongside SOC for six three-weekly cycles. Outcome measurements and statistical analysis The model generated lifetime predictions of costs, changes in survival duration, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Results and limitations The model predicted that docetaxel would extend survival (discounted quality-adjusted survival) by 0.89 yr (0.51) for metastatic PC and 0.78 yr (0.39) for nonmetastatic PC, and would be cost-effective in metastatic PC (ICER £5514/QALY vs SOC) and nonmetastatic PC (higher QALYs, lower costs vs SOC). Docetaxel remained cost-effective in nonmetastatic PC when the assumption of no survival advantage was modelled. Conclusions Docetaxel is cost-effective among patients with nonmetastatic and metastatic PC in a UK setting. Clinicians should consider whether the evidence is now sufficiently compelling to support docetaxel use in patients with nonmetastatic PC, as the opportunity to offer docetaxel at hormone therapy initiation will be missed for some patients by the time more mature survival data are available. Patient summary Starting docetaxel chemotherapy alongside hormone therapy represents a good use of UK National Health Service resources for patients with prostate cancer that is high risk or has spread to other parts of the body.
Citation
Woods, Beth S. et al. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. European Urology Oncology,
Publisher
Journal
Research Unit
PubMed ID
PubMed Central ID
Embedded videos
Additional Links
Type
Journal article
Language
en
Description
Series/Report no.
ISSN
25889311
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
This study was supported by the UK Medical Research Council (delegation to Swiss Group for Cancer Clinical Research [SAKK] in Switzerland) grant number MRC_MC_UU_12023/25 and the following funders: Cancer Research UK (grant number CRUK_A12459), Medical Research Council, Astellas, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis. The sponsors played no direct role in the study.